Motherwort (YiMuCao), a traditional Chinese herb, has been shown beneficial effects for women's diseases. This meta-analysis aimed to evaluate the efficacy and safety of motherwort injection add-on therapy to carboprost tromethamine for prevention of post-partum blood loss. A systematic literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, VIP and Wanfang from their inception to December 2017. Randomized controlled trials that determined the add-on effects of motherwort injection to carboprost for prevention of post-partum blood loss were eligible. Pooled risk ratio (RR) and mean difference (MD) with 95% confidence interval (CI) were used to summarize the effect sizes. Eight trials including 1276 pregnant women fulfilled the inclusion criteria. Prophylactic use of motherwort injection add-on therapy significantly reduced the post-partum 2 h (MD −127.5 mL; 95% CI −149.13 to −105.88) and 24 h (MD −146.85 mL; 95% CI −179.77 to −113.94) blood loss and incidence of post-partum hemorrhage (RR 0.28; 95% CI 0.17-0.45) than carboprost. Moreover, adjunctive treatment with motherwort injection significantly decreased the length of the third stage of labor (MD −3.41 min; 95% CI −4.33 to −2.49) and duration of lochia (MD −7.13 days; 95% CI −8.49 to −5.76). There was no statistical significant difference in the incidence of adverse events (RR 0.76; 95% CI 0.50-1.16). Prophylactic use of motherwort injection add-on therapy to carboprost tromethamine could reduce post-partum blood loss. However, more well-designed trials are necessary to confirm the findings of this study due to the methodological flaws of the included trials.
Introduction
Despite advances in medical care, post-partum hemorrhage (PPH) remains a leading cause of maternal mortality at delivery worldwide, 1 accounting for about 50 000 deaths per year. 2 The estimated global prevalence of PPH is approximately 6% of all deliveries. 3 PPH was associated with the increased rate of blood transfusion and the occurrence of serious anemia, subsequently prolonged length of hospital stay. 4 Uterine atony in pregnant women is responsible for over 80% of PPH. 5 Thus, prophylactic use of uterotonic agents can reduce the risk of post-partum blood loss. Oxytocin is recommended as the first choice in the prevention and treatment of PPH. 6 Other pharmacologic agents used for prevention and treatment of post-partum blood loss include ergometrine, misoprostol and tranexamic acid. Carboprost tromethamine (hemabate), a 15-methyl prostaglandin F2-alpha analogue, is also used to treat PPH due to its powerful uterotonic effect. In the high-risk women undergoing cesarean delivery, carboprost tromethamine was even more effective in prevention of PPH than oxytocin. 7 Traditional Chinese medicine (TCM) is widely used in the prevention and treatment of post-partum blood loss. Motherwort (YiMuCao), also known as Leonurus japonicus Houtt, has been used as a medicinal herb in China for thousands of years. 8 The research of motherwort mainly focused on its beneficial effects for women's diseases such as menoxenia, dysmenorrhea, amenorrhea and lochia. 9 A number of randomized trials have shown that motherwort injection alone or combined with other uterotonic agents has shown promising outcomes in prevention of post-partum blood loss. 10 However, this therapeutic approach has not undergone rigorous evaluation. Moreover, no previous metaanalysis has evaluated the additional benefits of motherwort injection add-on to carboprost tromethamine for prevention of post-partum blood loss.
The purpose of this meta-analysis was to evaluate the efficacy and safety of motherwort injection add-on therapy to carboprost tromethamine for prevention of post-partum blood loss using available randomized controlled trials (RCT).
Materials and Methods

Data sources and search strategy
This meta-analysis was performed and reported according to the Preferred Reporting Item for Systematic Review and Meta-analysis Statement Guideline.
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Ethical approval was not required because this study does not contain individual human participants or animals performed by any of the authors. A systematic literature search was conducted in PubMed, Embase, Cochrane Library, CNKI, VIP and Wanfang from their inception to December 2017, using combinations of the following Medical Subject Heading (MeSH) terms: 'motherwort injection' OR 'Yimucao injection' OR 'Yi mu cao injection' AND 'carboprost tromethamine' OR 'hemabate' OR '15-methyl prostaglandin F2-alpha' AND 'post-partum' OR 'cesarean' OR 'vaginal delivery' OR 'spontaneous labor' AND 'hemorrhage' OR 'hemorrhage' OR 'blood loss' AND 'randomized controlled trial' OR 'control' OR 'randomized'. In addition, we manually retrieved the references of the included trials and related review articles to identify any possible trials. No restrictions in language were applied.
Inclusion and exclusion criteria
Studies were eligible if they met the following inclusion criteria: (i) RCT comparing prophylactic use of motherwort injection plus carboprost tromethamine for prevention of post-partum blood loss; (ii) outcome measures included blood loss during post-partum 2 h and 24 h period, incidence of PPH (generally 24 h blood loss >500 mL for vaginal delivery and >1000 mL for cesarean section), length of the third stage of labor, duration of lochia and adverse events. Length of third stage of labor at cesarean section was defined by the time from the delivery of the infant until delivery of the maternal placenta. Studies were excluded if (i) motherwort was not used as an adjunctive therapy; (ii) any different regimen except for motherwort treatment; and (iii) self-control trial.
Data extraction and quality assessment
Two reviewers (W Meng and R Li) independently performed the study selection, extracted the data and evaluated the methodological quality of the included trials. Discrepancies between reviewers were resolved through discussion. For each included trial, we extracted the first author's name, publication year, sample size, maternal age, gestational age, type of delivery, estimation of blood loss method, regimen of both the motherwort and control arms and outcome measures. Cochrane risk of bias tool for RCT was used to evaluate the methodological quality of each included trials. This tool is based on the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome data, incomplete outcome data, selective reporting and others. The methodological quality was categorized as 'low risk', 'high risk' or 'unclear risk' of bias.
Data synthesis and analysis
The pooled effect sizes were reported as the mean difference (MD) with 95% confidence interval (CI) and risk ratio (RR) with 95% CI for the continuous and dichotomous variables, respectively. Statistical heterogeneity was tested using the Cochrane Q statistic and I 2 index. In case of statistically significant heterogeneity (P value of Cochrane Q statistic test <0.10 and I 2 > 50%), a random effect model was applied. Subgroup analyses were conducted by type of delivery. Sensitivity analysis was conducted by excluding anyone study at each time to check the robustness of the pooling summary. Publication bias was assessed by the Begg's test 12 and Egger's test. 13 Data analysis was performed using the RevMan (version 5.2, Oxford, UK) and STATA 12.0 statistical software (Stata Corp LP).
Results
Search results and study characteristics Figure 1 shows the study selection process. Briefly, the initial search of electronic databases yielded 205 articles after removal of duplicated records. After reviewing the titles and abstracts, 177 articles were excluded due to obviously not relevant. Twenty studies were further removed after applied the specific inclusion criteria. Finally, eight trials [14] [15] [16] [17] [18] [19] [20] [21] were included and analyzed in this meta-analysis. Table 1 described the characteristics of the included trials, a total of 1276 pregnant women were identified from the included trials. These trials were conducted in China and published from 2012 to 2017. The sample size in each trial varied from 102 to 308. One trial 15 was conducted on pregnant women undergoing vaginal delivery and others were pregnant women receiving cesarean section. The dose of carboprost tromethamine was 250 μg and total dose of motherwort injection ranged from 60 to 200 mg. Estimation of amount of blood loss was reported as gravimetric and volumetric method. Overall, methodological quality of each included trials was low to moderate with unclear risk of bias (Fig. 2) . All the trials reported the randomized allocation of participants. However, there was not sufficient information to judge whether randomization sequence or allocation concealment was conducted properly. 
Post-partum blood loss
All the included trials provided the volume of total post-partum 2 h blood loss and seven trials [14] [15] [16] [17] [18] [19] 21 reported the volume of post-partum 24 h blood loss. Meta-analysis showed that motherwort injection plus carboprost tromethamine significantly reduced the volume of total post-partum 2 h (MD −127.5 mL; 95% CI −149.13 to −105.88; Fig. 3a ) and 24 h (MD −146.85 mL; 95% CI −179.77 to −113.94; Fig. 3b ) blood loss than carboprost tromethamine group in a random effect model. With regarding to PPH incidence, a pooled analysis from six trials [15] [16] [17] [18] 20, 21 showed that prophylactic use of motherwort injection add-on therapy significantly reduced the incidence of PPH (RR 0.28; 95% CI 0.17-0.45; Fig. 4 ) in a fixed effect model. Subgroup analysis showed motherwort injection significantly reduced the PPH incidence for women undergoing cesarean section (RR 0.27; 95% CI 0.16-0.46) but not for women following vaginal delivery (RR 0.36; 95% CI 0.12-1.12). 
Length of the third stage of labor and duration of lochia
Three trials 14, 20, 21 provided the data on the length of the third stage of labor and four trials [16] [17] [18] [19] reported the duration of lochia as an outcome measure. Metaanalysis showed that prophylactic use of motherwort injection add-on therapy significantly reduced the length of the third stage of labor (MD −3.41 min; 95% CI −4.33 to −2.49; Fig. 5a ) and duration of lochia (MD −7.13 days; 95% CI −8.49 to −5.76; Fig. 5b ) in a random effect model.
Adverse events
Four trials 14, 16, 20, 21 provided the adverse events as the outcome measure. The frequently reported adverse events included nausea, vomiting, chest tightness, 
Sensitivity analysis and publication bias
When we sequentially removed anyone study at each turn, the pooled summary of each outcome for the remaining trials remained statistically significant. There were no statistical evidences of publication bias on the post-partum 2 h blood loss (P = 0.386 for Begg's test and P = 0.514 for Egger's test) and postpartum 24 h blood loss (P = 0.764 for Begg's test and P = 0.975 for Egger's test).
Discussion
The main finding of this meta-analysis is that prophylactic use of motherwort injection add-on therapy to carboprost tromethamine significantly decreased Figure 4 Forest plots showing risk ratio of post-partum hemorrhage incidence comparing motherwort injection plus carboprost to carboprost therapy. post-partum 2 h and 24 h blood loss volume, and incidence of PPH after delivery than carboprost tromethamine. In addition, motherwort injection also significantly reduced the length of the third stage of labor and duration of lochia. These findings supported that prophylactic motherwort injection in combination with carboprost tromethamine given during delivery achieved additional benefits, suggesting a synergic effect of these two agents. The average length of the third stage of labor is 8-9 min. 22 Prolongation of the third stage of labor can cause an increase in the incidence of PPH. 23 The evidence of active management of the third stage of labor reduces the occurrence of PPH has been well established. 24 Results of this meta-analysis suggested that motherwort injection in combination with carboprost could shorten the third-stage duration by 3.41 min than carboprost. This finding supported for use of motherwort injection as adjunctive therapy during the third stage of labor. In addition, the combined therapy also reduced the duration of lochia by 7.13 days, which revealing motherwort can promote the recovery of the uterus. Furthermore, motherwort injection combined with carboprost was superior to carboprost alone in promoting the drop the height of post-partum uterus. 15, 16 Post-partum blood loss is higher in cesarean section compared to vaginal delivery. 25 Considering that the increasing rate of cesarean section, the incidence of PPH may become more common. However, prevention of post-partum blood loss in women undergoing cesarean is challenging. Our subgroup analysis indicated that prophylactic use of motherwort injection could significantly reduce the incidence of PPH only in women following cesarean delivery but not vaginal delivery. This finding revealed that motherwort injection possibly more suitable for women undergoing cesarean delivery.
The difference of delivery modes appeared to affect the effect of motherwort injection. The effect of motherwort injection on post-partum blood loss (by continuous variable analysis) was stronger in women undergoing cesarean section than those with vaginal delivery. When analyzed by the dichotomous variables, motherwort injection significantly decreased the incidence of PPH among women undergoing cesarean section but not in vaginal delivery. However, interpretation of these results should be with caution. These findings may be explained by lack of statistical power due to small number of PPH cases and relatively low post-partum blood loss in the vaginal delivery. In fact, prophylactic use of motherwort injection add-on therapy to carboprost tromethamine significantly reduced the volumes of post-partum 2 h and 24 h blood loss regardless of delivery mode.
Carboprost tromethamine is mainly used for termination of pregnancy, management of labor and prevention and treatment uterine atony. 26 An initial dose of 250 μg is recommended for carboprost and the total dose should not exceed 2 mg. In addition to carboprost, motherwort injection combined with oxytocin 27, 28 or misoprostol 29 also showed benefits in prevention of PPH. Coagulation disorder is another cause of PPH. 26, 30 Motherwort is traditionally used to invigorate the blood and regulate menses. 31 Alkaloids, diterpenoid and circular peptide extracted from motherwort are associated with its mechanism of activating blood and resolving stasis. 32 Moreover, an experimental study showed that cyclopeptides and alkaloids extracted from motherwort could directly act on the uterine smooth muscle strips isolated from normal rats. 33 The effect of uterine smooth muscle shrinking may facilitate placenta expulsion and the collapse of the uterus after delivery.
With regard to adverse events of the combined therapy, these events were mild and transient. The most common side effects associated with carboprost used were vomiting and diarrhea. Others include headache, hypertension, flushing of the skin and bronchial asthma. There was no statistical difference in the incidence of adverse events in this meta-analysis. Namely, prophylactic use of motherwort injection add-on therapy to carboprost did not increase the adverse events.
Limitations of this meta-analysis are inherent to the methodological flaws of the included trials. First, suboptimal methodological quality of the included trials was an important limitation. Most of the included trial did not clearly describe allocation concealment, blinding method and adverse events. More welldesigned trials with rigorous blinding, randomization and allocation concealment procedures are necessary in the future studies. Second, significant heterogeneity across studies was found among pooling continuous variables, so a random effect model was used to pool these trials. The sources of heterogeneity may be correlated to the type of delivery, surgical experience of the obstetricians, method of blood collection or estimation and regimen of motherwort therapy. Third, the results of this meta-analysis may be not applied for women delivering vaginally because the majority of the included trials primarily reported on pregnant women undergoing cesarean delivery. Fourth, the incidence of PPH is dependent on the accuracy of blood loss estimation. However, most of the included trials visually estimated blood loss by volumetric and/or gravimetric method which has considerable inaccuracy. Finally, participants' selection process did not consider the syndrome differentiation of TCM could have lowered the efficacy and safety of motherwort treatment.
In conclusion, this meta-analysis reveals that prophylactic use of motherwort injection add-on therapy to carboprost tromethamine achieved additional benefits in terms of reducing post-partum blood loss, length of third stage of labor and duration of lochia, especially for women undergoing cesarean section. However, more well-designed trials are necessary to confirm these important potential benefits of motherwort injection as add-on therapy due to the methodological flaws of the analyzed trials.
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